Clinical outcome and prognostic factors for patients treated within the context of a phase I study: the Royal Marsden Hospital experience
2008

Prognostic Factors in Phase I Cancer Trials

Sample size: 212 publication Evidence: moderate

Author Information

Author(s): Tirelli U

Primary Institution: National Cancer Institute

Hypothesis

Can patients with prostate cancer who are not pretreated with chemotherapy have better outcomes in phase I trials compared to those who are pretreated?

Conclusion

Patients with prostate cancer who were not pretreated with chemotherapy had significantly better outcomes than those with non-urological cancers.

Supporting Evidence

  • 54 patients (25%) had prostate cancer.
  • 37 patients (68%) were not pretreated with chemotherapy.
  • Patients with urological cancers had better outcomes than those with non-urological cancers.

Takeaway

This study found that prostate cancer patients who didn't have chemotherapy before a trial did better than those who did.

Methodology

Analysis of outcomes from 29 phase I trials involving 212 patients.

Limitations

The study does not compare outcomes between pretreated and non-pretreated prostate cancer patients directly.

Participant Demographics

54 patients (25%) had prostate cancer, 37 (68%) were not pretreated with chemotherapy.

Statistical Information

P-Value

0.001

Statistical Significance

p=0.001

Digital Object Identifier (DOI)

10.1038/sj.bjc.6604648

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication